Disclosed are methods for inhibiting Ras activity such as cell proliferation
associated with vascular injury such as post-angioplasty restenosis and atherosclerosis.
Preferred Ras antagonists are S-trans-trans farnesylthiosalicylic acid (FTS) and
structurally related compounds (or analogs) thereof.